Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

DIABETES CARE

AMER DIABETES ASSOC

1. Amgen
2. AstraZeneca
3. Boehringer Ingelheim
4. Bristol-Myers Squibb
5. Eli Lilly
6. Hoffmann-La Roche
7. Janssen
8. Sharp Dohme GmbH
9. Novartis Pharma AG
10. Novo Nordisk A/S
11. Sanofi Pharma
12. Takeda
13. Abbott
14. Astellas
15. Diabetes UK
16. Engineering and Physical Sciences Research Council
17. European Association for the Study of Diabetes
18. Ferring
19. GlaxoSmithKline
20. Lilly
21. Medical Research Council
22. Medtronic
23. Merck
24. National Health Service
25. Pfizer
26. Sanofi
27. Shire
28. Wyeth